Geopolitical tensions have brought a lot of uncertainty to the markets, but investors know one thing for certain: Those tensions will cause countries to put more money into their defense systems and militaries. When a significant amount of capital flows... Read more
Macroeconomic cycles are often defined by the environments in which certain assets tend to perform best. For example, real assets such as commodities and natural resource stocks have historically held up better during inflationary periods. Since September 2024, however, U.S.... Read more
Electrical distribution equipment manufacturer Forgent Power Solutions files for an estimated $300 million IPO February 5, 2026 News Electrical equipment maker Forgent Power Solutions prices US IPO at $27 midpoint, raising $1.5 billion Forgent Power Solutions, which manufactures electrical distribution... Read more
Hair loss biotech Veradermics files for a $100 million IPO February 4, 2026 News Hair loss biotech Veradermics prices upsized IPO at $17, above the range Veradermics, a Phase 3-ready biotech developing therapies for hair loss, raised $256 million by... Read more
Micro-cap biotech Lakewood-Amedex Biotherapeutics files for a Nasdaq direct listing IPO Overview Lakewood-Amedex Biotherapeutics, which is developing a topical antimicrobial treatment for drug-resistant infections, filed on Friday for a direct listing on the Nasdaq. The shares of common stock listed... Read more
Budget furniture retailer Bob’s Discount Furniture files for an estimated $400 million IPO February 5, 2026 News Budget furniture retailer Bob’s Discount Furniture prices IPO at $17, the low end of the range Bob’s Discount Furniture, a budget retailer of... Read more
Tech and finance-focused SPAC Lafayette Digital Acquisition I prices $250 million IPO January 9, 2026 Tech and finance-focused SPAC Lafayette Digital Acquisition I prices $250 million IPO IPO Overview Lafayette Digital Acquisition I, a blank check company targeting the... Read more
Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO February 4, 2026 News Immuno-responsive cancer biotech Eikon Therapeutics prices upsized IPO at $18 high end Eikon Therapeutics, a Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers,... Read more
Investing directly in artificial intelligence startups promises lofty returns but is also risky, as it is far from certain who will be left by the wayside in the boom and whether the industry will grow as forecast. To help reduce... Read more
2025 was a challenging year for Bitcoin bulls. By Dec. 31, Bitcoin was down 6.3% on the year, following a 121% gain in 2024 and a 155% gain in 2023. “We are cautiously optimistic on Bitcoin heading into 2026 thanks... Read more
If tax efficiency is a top priority, there are quite a few ways to shield more of your investment gains from Uncle Sam. Asset location should come first. Americans have access to several tax-sheltered accounts, including workplace 401（k） plans, Roth... Read more
How to Make Money in Any Market Instant New York Times Bestseller Renowned personal finance expert, bestselling author, host of CNBC’s Mad Money, and cohost of Squawk on the Street Jim Cramer returns with how to make money in... Read more